Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share

The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
Numerator
Net loss - before noncontrolling interest	$	(29,932	)	$	(13,668	)	$	(78,666	)	$	(36,447	)
Net loss attributable to noncontrolling interest		3,806			1,441			10,143			3,318
Net loss - as reported, attributable to PAVmed Inc.	$	(26,126	)	$	(12,227	)	$	(68,523	)	$	(33,129	)
Series B Convertible Preferred Stock dividends – earned	$	(71	)	$	(67	)	$	(209	)	$	(216	)
Net loss attributable to PAVmed Inc. common stockholders	$	(26,197	)	$	(12,294	)	$	(68,732	)	$	(33,345	)
Denominator
Weighted average common shares outstanding, basic and diluted		89,758,927			83,307,170			87,724,124			79,873,583
Net loss per share
Basic and diluted
Net loss - as reported, attributable to PAVmed Inc.	$	(0.29	)	$	(0.15	)	$	(0.78	)	$	(0.41	)
Net loss attributable to PAVmed Inc. common stockholders	$	(0.29	)	$	(0.15	)	$	(0.78	)	$	(0.42	)

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

	September 30,
	2022		2021
Stock options and restricted stock awards		12,586,571		10,214,448
Series Z Warrants		11,937,450		13,887,814
Series W Warrants		—		377,873
Series B Convertible Preferred Stock		1,182,101		1,091,448
Total		25,706,122		25,571,583